Business Wire

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides

3.12.2025 14:00:00 CET | Business Wire | Press Release

Share

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides.

Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries.

The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer.

Strong validation across international cohorts

Recently published research at ESMO 20251 highlights robust results achieved across multiple independent cohorts from Centre Léon Bérard (France), Washington University School of Medicine in St. Louis (USA), and King’s College London (UK).

Trained on an enriched cohort of germline BRCA mutation patients from Gustave Roussy, BRCAura RUO demonstrated strong and reproducible performance:

  • Area Under the Curve (AUC) of 80% in predicting mutation status
  • Ability to rule out approximately 40% of patients unlikely to carry gBRCA mutations with a high sensitivity of 93%
  • Robustness across different staining types and scanners, ensuring consistent performance across real-world conditions

Supporting research and accelerating access to testing

“We developed BRCAura with the vision of expanding access to gBRCA testing and identifying more patients at risk of harboring BRCA mutations to determine the best personalized treatment approach,” explains Meriem Sefta, Chief Diagnostic Officer. “This first step is being leveraged in research settings, to enhance workflows, but also to gain an understanding of how morphological factors could be systematically leveraged to expand and accelerate gBRCA testing.”

“These recent results are promising as they highlight a robustness to pre-analytical and clinical variability that is a necessary requirement for any screening solution to optimize clinical routine diagnosis of gBRCA mutations” says Sheeba Irshad, Professor of Cancer Immunology at King’s College London and Breast Cancer Medical Oncologist. “While further evaluation will be essential, approaches like this may eventually help support earlier and better-informed decisions about patient management.”

These results support BRCAura RUO as a powerful, standardized histopathology-based solution with increased reliability when compared to current clinical scoring methods relying upon age, and family history. These methods, typically validated, remain highly diverse in approach across different hospital settings. This paves the way for a clinically approved version of the device to introduce a more standardized approach to help streamline patient selection for genetic testing and next-generation sequencing (NGS). Additionally, by ruling out patients unlikely to carry the gene, BRCAura could help expand testing access to those patients not routinely considered for genetic testing.

“To advance our bold oncology ambitions, we are building a collaborative ecosystem across leading AI companies and academia to develop AI solutions that can transform care,” said Greg Rossi, Senior Vice President Oncology, Europe and Canada, AstraZeneca. “These validation results underscore how histopathology-based AI can help bridge the gap between pathology and genomics – paving the way for faster and broader genetic testing.”

The PortrAIt consortium is a French consortium financed by the government within the framework of France 2030 and by the European Union - Next Generation EU within the framework of the France Relance Plan. It consists of the following members:
Owkin
Gustave Roussy
Centre Léon Bérard
Unicancer
Cypath
Tribun Health

About Owkin

Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. Owkin’s Dx division is a leader in clinically validated digital pathology AI testing. These solutions seamlessly integrate into digital pathology workflows, enhancing patient diagnosis and therapeutic decision-making through advanced biomarker screening and outcome prediction. Owkin’s proven track record and platform spans utility for pharma R&D and clinical trials to regulatory-approved IVD tests for routine clinical use.

About Gustave Roussy

Ranked first in France, first in Europe and sixth in the world, Gustave Roussy is a centre of global expertise entirely dedicated to patients living with cancer. The Institute is a founding pillar of the Paris-Saclay Cancer Cluster. Source of therapeutic innovations and diagnostic breakthroughs, the Institute welcomes nearly 50,000 patients each year, including 3,500 children and adolescents, and develops an integrated approach combining research, care and teaching. An expert in rare cancers and complex tumours, Gustave Roussy treats all cancers at all stages of life. It offers its patients personalised care that combines innovation and humanity, taking into account both care and the physical, psychological and social quality of life. With 4,100 employees at two sites, Villejuif and Chevilly-Larue, Gustave Roussy brings together the expertise essential for high-level cancer research; 32% of treated patients are included in clinical studies. To find out more about Gustave Roussy and follow the Institute’s news: www.gustaveroussy.fr/en, X, Facebook, LinkedIn, Instagram and Bluesky.

About Centre Léon Bérard

The Centre Léon Bérard (CLB) is a regional, national and internationally recognized reference cancer center and one of twenty Comprehensive Cancer Centres in France, providing a global management of cancer patients from diagnosis to treatment and beyond. The Centre excels in multidisciplinary research, and reinforces the bench-to-bedside process through facilitating translational research to accelerate innovation and patient access to diagnoses and therapies.

About King’s College London

King’s College London is amongst the top 35 universities in the world and 5th best in the UK (QS World University Rankings 2026), and one of England’s oldest and most prestigious universities. For nearly 200 years, King’s students and staff have used their knowledge and insight to make a positive impact on people, society and the planet. Focused on delivering positive change at home in London, across the UK and around the world, King’s is building on its history of addressing the world’s most urgent challenges head on to accelerate progress, make discoveries and pioneer innovation. World-changing ideas. Life-changing impact: kcl.ac.uk/news

1Tchita, O. et al. Development and validation of BRCAura: A histology model to predict germline BRCA1/2 mutations from HR+/HER2- breast cancer images, poster 327P)

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203872467/en/

Contacts

Owkin press contact: malika.labou-ext@owkin.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press Release

Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press Release

Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press Release

Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press Release

NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous

Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press Release

Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redundant Command and Data Handling systems as well as the Instrument Command and Data Handling systems for both the Wide Field Instrument and Coronagraph Instrum

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye